SEATTLE, WA--(Marketwired - June 16, 2014) -
Atossa Genetics Inc., (NASDAQ: ATOS
) today announced that Steven C. Quay, M.D., Ph.D., Chairman, CEO and President will be a featured presenter at the Life Science Innovation Northwest 2014 Exposition (LSINW), North America's largest, fully-integrated Life Science Exposition, on Friday, June 20, 2014 from 1:15 to 1:35 pm PDT at the Washington State Convention Center, Seattle, WA.
About Life Science Innovation Northwest
Life Science Innovation Northwest is dedicated to bringing together world-class innovators in biopharma, medical technology, non-profits, research, global health, digital health, biofuels and veterinary medicine. Public and private investors, investment bankers and industry executives focused on business development and partnering opportunities in life sciences find Life Science Innovation Northwest one of the most productive conferences they attend. For more information please visit http://www.washbio.org/displaycommon.cfm?an=1&subarticlenbr=413
About Atossa Genetics
Atossa Genetics Inc. is focused on improving breast health through the development of laboratory-developed tests (LDTs), medical devices and therapeutics. The Company's LDTs are being developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. The LDTs and the Company's medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For additional information, please visit www.atossagenetics.com.
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, including timing of review by the FDA of 510(k) submissions, and actions related thereto, whether Atossa can submit additional information to the FDA in a timely fashion and whether the FDA will find that information acceptable and/or request additional information, the outcome of the FDA re-inspection completed on March 14, 2014, the outcome or timing of regulatory clearances needed by Atossa to sell its products, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, recalls of products, the efficacy of Atossa's products and services, performance of distributors, estimated future expenses and cash needs, whether Atossa can launch in the United States and foreign markets the additional tests, devices and therapeutics in its pipeline in a timely and cost effective manner, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.